Fluoxetina

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluoxetina

Property Description
Active ingredient Fluoxetine hydrochloride
Form Capsule, Tablet, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulating mood and emotional balance
Origin Synthetic compound

What Type of Medicine is Fluoxetina?

Fluoxetina, containing the active ingredient Fluoxetine, is a prescription-only medicine that belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class of drugs, primarily categorized as an antidepressant and psychotropic agent. This classification reflects its fundamental purpose as a therapeutic tool designed to modulate chemical signaling in the central nervous system. As an SSRI, Fluoxetine is a synthetic compound distinguished from older classes of antidepressants, such as tricyclics, by its highly selective action, focusing almost exclusively on a single neurotransmitter. The medicine is intended for oral (systemic) administration and is widely known under major commercial names like Prozac, establishing its long-standing recognition in the medical community.


Fluoxetine: Composition, Forms, and Origin

The core of Fluoxetina is the active ingredient Fluoxetine, typically utilized in its crystalline salt form, Fluoxetine hydrochloride, which is entirely a synthetic compound developed in a laboratory. This single-ingredient product is manufactured into various pharmaceutical preparations to suit patient needs. The common high-level dosage forms include the solid capsule and tablet, which are swallowed, and a liquid oral solution, offering a key differentiating factor by providing an alternative to solid forms for patients who have difficulty swallowing. The inactive components consist of standard pharmaceutical excipients appropriate for these preparations.


What is the General Purpose of a Selective Serotonin Reuptake Inhibitor?

The general purpose of a Selective Serotonin Reuptake Inhibitor like Fluoxetina is to help restore a more stable balance of key mood-regulating chemicals in the brain. The drug achieves this by performing the fundamental action of selective inhibition of serotonin reuptake, which temporarily prevents nerve cells from quickly reabsorbing the released serotonin. This mechanism results in the enhancement of serotonergic neurotransmission, helping to normalize the signaling pathways that influence emotional states, which is the foundational goal for using this type of psychotropic agent in scenarios such as pervasive mood disruption. The main action is based on the specific inhibition of serotonin uptake.

What side effects are possible with Fluoxetina?

Possible Side Effects and Safety Information

The safety profile of Fluoxetine is officially structured by regulatory authorities based on the frequency and the physiological system affected. The majority of reported adverse reactions are classified as Very Common or Common and typically involve the nervous system or the gastrointestinal tract.

Official Adverse Reaction Classification

Frequency Classification Key Adverse Reactions (Examples)
Very Common (1/10) Insomnia, Headache, Nausea, Diarrhea, Fatigue
Common (1/100 to < 1/10) Anxiety, Tremor, Somnolence, Sexual dysfunction, Reduced appetite
Rare (1/10,000 to < 1/1,000) Serotonin Syndrome, Hyponatraemia, Severe Cutaneous Reactions

Serious adverse reactions, though rare, are documented in regulatory labeling and include Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like events, severe cutaneous adverse reactions (SCARs), and abnormal bleeding events.

Safety Considerations and Constraints

Certain safety patterns are defined relative to the exposure period. Official documents state that the risk for the emergence or worsening of suicidal thoughts and behaviors must be closely observed, particularly early in treatment or following a dose change, especially in children, adolescents, and young adults.

Specific safety constraints are also defined: Fluoxetine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs) due to the documented risk of developing Serotonin Syndrome. For patients with hepatic impairment, a modification in dosing schedule may be necessary due to reduced drug clearance, as stated in regulatory information.

Overdose and Emergency Response

Fluoxetine overdose is detailed in official regulatory sources by specific clinical manifestations and mandated emergency actions. Documented overdose presentations commonly involve central nervous system excitation, gastrointestinal distress, and cardiovascular abnormalities. Officially listed signs include seizures (including generalized), somnolence, agitation, tremor, and vomiting. Severe outcomes listed in regulatory documents are Serotonin Syndrome, significant QTc prolongation, and dangerous Ventricular Arrhythmias such as Torsade de Pointes, with death and respiratory depression reported in the most serious cases. Increased severity is associated with the co-ingestion of Fluoxetine with other drugs. The regulatory profile mandates that individuals seek immediate medical attention and contact a Poison Control Center upon suspicion of overdose. Urgent help must be sought if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Management requires providing symptomatic and supportive treatment and ensuring continuous ECG monitoring due to the confirmed status that no specific antidote is known.

Therapeutic Uses of Fluoxetina

Fluoxetine is commonly used to help with a range of conditions characterized by periods of heightened emotional and behavioral symptoms, providing supportive relief that helps patients cope more steadily. Its use is relevant across therapeutic areas where additional symptomatic support is needed. The medication is applied in managing Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder.


Therapeutic Focus and Symptom Relief

Fluoxetine is commonly used when symptoms intensify and supportive relief is needed, often during phases where functional stability becomes affected. It helps address symptom clusters that may become intense or disruptive, such as profound sadness, intrusive, repetitive thoughts, and recurrent, unexpected fear. The medication supports the patient during difficult episodes by helping to ease the overall symptom load.

“It is commonly used across conditions presenting with acute episodes and helps maintain a sense of stability when symptoms are more noticeable.”

This includes scenarios relevant for helping to ease severe binge-purge behaviors and may assist with managing the intense cyclical mood swings associated with PMDD. For patients with MDD, the medication provides support that helps ease the overall symptom burden and may assist with managing the distressing manifestations.


Quick Fact: Relief for Intrusive Thoughts (Symptoms that interfere with daily functioning, such as persistent obsessions in OCD).

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Fluoxetina?

Fluoxetina eligibility is determined strictly by regulatory guidelines, focusing on absolute contraindications, age restrictions, and patient health status.

Absolute Contraindications (Must Not Use):

The medicine is strictly contraindicated for patients who are currently taking Monoamine Oxidase Inhibitors (MAOIs), including linezolid, due to the severe risk of Serotonin Syndrome. It is also prohibited for patients taking Thioridazine or Pimozide due to the risk of serious cardiac issues, such as QTc prolongation. Individuals with a known hypersensitivity to fluoxetine must also not use the medication.

Age and Condition-Based Restrictions:

Population Group Eligibility Status (Regulatory)
Adults (18+) Generally eligible for all labeled indications.
Pediatric Patients Restricted: Approved only for Major Depressive Disorder (ge 8 years old) and Obsessive-Compulsive Disorder (ge 7 years old).
Hepatic Impairment Conditional: Eligible, but requires a lower or less frequent dosing regimen due to reduced clearance.
Pregnancy/Lactation Conditional: Use during pregnancy is allowed only if the benefit justifies the potential risk; use during lactation is generally not recommended.

Fluoxetina use also requires caution in patients with a history of seizures or specific cardiac risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fluoxetina (Fluoxetine) has officially documented interactions that require specific restrictions and cautions according to regulatory authorities. These constraints are primarily defined by the drug's potent inhibitory effect on the CYP2D6 enzyme and the risk of combined pharmacodynamic effects.

Formally Contraindicated Combinations

Co-administration with the following substances is strictly prohibited due to severe interaction risk:

  • Monoamine Oxidase Inhibitors (MAOIs): Including Linezolid and Intravenous Methylene Blue.
  • Pimozide and Thioridazine.

Key Interaction Categories

Interaction Type Examples of Affected Substances Regulatory Requirement
Metabolic (CYP2D6 Inhibition) Tricyclic Antidepressants (TCAs), Phenytoin, Carbamazepine, Class IC Antiarrhythmics. May cause elevated plasma concentrations of co-administered medicines, requiring caution.
Pharmacodynamic (Serotonin Risk) Triptans, Lithium, Tramadol, Tryptophan, St. John's Wort. Increases the labeled risk of Serotonin Syndrome.
Pharmacodynamic (Bleeding Risk) Warfarin, NSAIDs, Aspirin. Potentiates the risk of bleeding events, requiring careful monitoring.

Timing and Separation Requirements

To manage interaction risk, a mandatory waiting period of 5 weeks must pass after discontinuing Fluoxetine before initiating an MAOI or Thioridazine. Conversely, at least 14 days must elapse after stopping an MAOI before starting Fluoxetine.

Other Interactions

Official labeling advises to avoid alcohol use and notes that the interaction profile may be exacerbated in patients with hepatic impairment due to reduced drug clearance.

Mechanism of Action

How Fluoxetina Works: Mechanism of Action

Fluoxetine acts as a selective inhibitor of the Sodium-dependent Serotonin Transporter (SERT) on presynaptic neurons. This molecular interaction blocks the reuptake of serotonin (5-HT) from the synaptic cleft, resulting in a sustained increase in the concentration of free 5-HT available to stimulate postsynaptic receptors. This initial effect alters activity within central serotonergic circuits.

Beyond this primary action, the resulting persistent elevation of serotonin initiates a slower, chronic mechanistic cascade involving changes in gene expression and the upregulation of Brain-Derived Neurotrophic Factor (BDNF). This mechanism influences neurogenesis and synaptic remodeling in specific brain regions, contributing to the regulation of circuits involved in stress response and emotional signaling.

Fluoxetine also engages in secondary receptor modulation, acting as an antagonist at the 5-HT2C receptor and an agonist at the Sigma-1 (sigma1) receptor. This broader influence contributes to the resulting signaling pattern and affects systemic regulation by modulating pathways like the Hypothalamic-Pituitary-Adrenal (HPA) axis and general neuronal excitability.

Dosage and Administration Information

How to Use Fluoxetina: Administration Guidelines

Fluoxetina (fluoxetine hydrochloride) is administered via the oral route as the designated method of intake. The medicine is typically taken once daily in the morning, though higher daily doses may be divided for administration in the morning and at noon. Administration may occur with or without food, as absorption is not significantly affected by meals.


Dosing and Scheduling Patterns

Instructions define specific starting and maintenance dose ranges depending on the condition. For instance, the initial dose for Major Depressive Disorder (MDD) is typically 20 mg once daily, while the dose for Bulimia Nervosa is a fixed 60 mg once daily. Weekly use is an option with the 90 mg delayed-release capsule, which is to be initiated seven days after the last daily dose.

Administration also varies for specific forms: The oral solution requires precise measurement using a marked device, and delayed-release capsules must be swallowed whole, without being cut, crushed, or chewed.


Population Adjustments

Guidelines address dosage adjustments for specific patient groups. For individuals with hepatic impairment, a lower or less frequent dosage should be used. Furthermore, caution is generally advised for older adults, with guidelines suggesting the daily dose usually does not exceed 40 mg to 60 mg. If a dose is missed, standard instructions state to take the next dose at the regular time and to avoid taking two doses to make up for the one missed.

Recent Clinical Evidence

Fluoxetina: Recent Clinical Evidence

The research on Fluoxetina is based on numerous clinical trials that examined patterns in specific conditions. These studies track changes in symptoms and describe patterns observed in the different study populations. It is important to remember that study results reflect the specific conditions under which they were conducted and research provides context, but not individual predictions.


Evidence for use in Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

Research for MDD primarily relied on short-term Randomized Controlled Trials (RCTs) and long-term maintenance protocols in adult and pediatric populations. Studies monitored symptom evolution and patterns of symptom return. Similarly, OCD research included acute RCTs and observational follow-up studies in both adult and pediatric groups, primarily examining changes in standardized symptom severity scales. In both areas, findings related to measured symptom change in children and adolescents were mixed, and evidence quality varies across studies.


Evidence for use in Bulimia Nervosa, Panic Disorder, and PMDD

Evidence for Bulimia Nervosa was explored in short-term, placebo-controlled trials focusing on specific eating behaviors, although this core data is drawn from older literature and comparative evidence is limited. Panic Disorder research evaluated short-term RCTs that monitored acute changes in anxiety and stress scores, but recent overviews suggest the data quality varies due to imprecision. For Premenstrual Dysphoric Disorder (PMDD), specialized controlled trials examined cyclical symptoms under different dosing schedules, but some reported high participant dropout and modest sample sizes.


Long-term Research and Uncertainties

Long-term outcomes have been examined through maintenance studies tracking patterns of symptom return, yet long-term effects are not fully established across all patient groups, as follow-up durations were limited in many primary trials. Dedicated research for older adults and populations with specific complicating conditions is sparse. A key research limitation is that data show patterns related to what is known—and what is still uncertain—regarding functional status and sustained quality of life outcomes.

Key Studies & References World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) Classification System - N06AB03

Frequently Asked Questions (FAQ)

Common questions about Fluoxetina (FAQ)


Q: How quickly do people typically start noticing effects from Fluoxetina?

Studies and official information indicate that the full therapeutic effect for conditions like Major Depressive Disorder may not be fully apparent until 3 to 4 weeks after starting treatment. In clinical observations, some initial changes in symptoms related to sleep, energy, or appetite may be reported within the first one to two weeks of starting treatment.


Q: Is it necessary to take Fluoxetina for a long time?

Regulatory studies show that Fluoxetina is indicated for both acute treatment and long-term maintenance treatment of certain conditions. This suggests that treatment often continues after a patient initially feels better to manage the risk of symptom recurrence. The duration of therapy is typically based on the specific condition and the assessment of continuing therapeutic need.


Q: Can Fluoxetina cause weight gain or weight loss?

Official adverse reaction data includes reports of both weight loss and reduced appetite in clinical trials. Any changes in weight are generally modest and can sometimes be related to recovery from the underlying condition rather than the medication itself.


Q: Can someone stop taking Fluoxetina suddenly?

Regulatory documents advise against the abrupt discontinuation of Fluoxetina treatment. Stopping this medicine suddenly has been associated with the occurrence of withdrawal reactions, which may include symptoms like dizziness and nausea. Any decision to change treatment requires discussion with a healthcare provider.


Q: Is Fluoxetina known to affect sleep patterns?

Official adverse reaction data lists both insomnia (difficulty sleeping) and somnolence (unusual sleepiness or drowsiness) as common or very common side effects. This indicates that Fluoxetina can impact a person's overall sleep patterns.


Q: Are there any major food or drink restrictions while using Fluoxetina?

Regulatory labeling specifically advises patients to avoid the use of alcohol while taking fluoxetine. Official labeling advises avoiding alcohol, as co-use is known to increase nervous system side effects such as dizziness and drowsiness.


Q: Can Fluoxetina be taken during pregnancy?

Official documents state that use during pregnancy is conditional, allowed only if the potential benefit is judged to justify the potential risk to the fetus. Official labeling notes that newborns exposed to SSRIs late in the third trimester have developed complications requiring prolonged hospitalization, breathing support, and tube feeding.


Q: Does Fluoxetina change how other medicines are processed in the body?

Yes, regulatory documents describe Fluoxetina as a potent inhibitor of the CYP2D6 enzyme, which is a system in the liver that breaks down many other medicines. This action can lead to higher concentrations of certain co-administered medicines in the bloodstream.


Q: Is it common to feel worse when first starting Fluoxetina?

Official warnings state that patients must be closely monitored for the emergence or worsening of symptoms like agitation or irritability, particularly early in treatment or after a dose change. This monitoring is an official safety precaution, particularly in children, adolescents, and young adults.


Q: Does Fluoxetina cause problems with concentration or memory?

Regulatory labeling notes the potential for cognitive and motor impairment. This means the medicine may affect mental functions such as judgment, thinking, and memory. This is a factor that patients may need to consider when performing daily activities.


Q: Are there different strengths or forms of Fluoxetina available?

Yes, official regulatory documents list Fluoxetina as being available in different dosage forms. These typically include solid forms like the capsule and tablet, as well as a liquid oral solution, all available in various standard strengths.


Q: How does Fluoxetina compare to older types of antidepressants?

Fluoxetina belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class. This class is generally distinguished from older classes of antidepressants, such as tricyclics or MAOIs, by its more selective mechanism of action.


Q: Can Fluoxetina cause any issues with sexual function?

Yes, official adverse reaction data lists sexual dysfunction as a common side effect reported in clinical trials. This term may include issues related to desire, arousal, and the ability to reach orgasm.


Q: Does Fluoxetina affect blood pressure?

High blood pressure is not generally listed as a common side effect of Fluoxetina. However, regulatory labeling documents that high blood pressure can be a potential symptom of Serotonin Syndrome, which is a rare but serious adverse reaction.


Q: What is the typical time frame for reaching the full effect of Fluoxetina?

According to official regulatory and clinical sources, the full therapeutic effect of Fluoxetina may take 3 to 4 weeks to fully develop. Studies used to establish efficacy are often conducted over treatment periods of 5 to 16 weeks.


Q: Is Fluoxetina used for anxiety disorders?

Fluoxetina is officially approved by regulatory bodies for the treatment of Panic Disorder (with or without agoraphobia) and Obsessive-Compulsive Disorder (OCD), both of which are classified as anxiety-related conditions.


Q: Does Fluoxetina interact with birth control pills?

Official labeling does not typically list hormonal contraceptives as a key interaction risk based on existing data. The general drug interaction profile is complex, but current information does not indicate a major interaction concern between these two types of medications.


Q: Can men and women experience different side effects from Fluoxetina?

Clinical observations have noted sex-related differences regarding Adverse Drug Reactions (ADRs). For example, some data indicates a difference in the reported rates of sexual dysfunction between male and female patients taking SSRIs.


Q: What is the risk of having severe side effects from Fluoxetina?

While the overall rate of severe adverse events is low, official labeling documents specific rare risks. These include potentially life-threatening conditions such as Serotonin Syndrome and severe cutaneous adverse reactions. These are serious adverse reactions where immediate professional medical assessment is necessary.


Q: Are there known effects of Fluoxetina on appetite?

Yes, the official adverse reaction profile includes reduced appetite as a common side effect. This is a factor associated with the modest weight loss sometimes observed in clinical trials.


Q: What is the maximum duration for a course of Fluoxetina treatment?

There is no universally defined maximum duration for treatment documented in regulatory labeling. Official studies include long-term maintenance protocols, and the total duration is based on the specific condition and the needs of the individual patient over time.


Q: Does Fluoxetina cause noticeable changes in energy levels?

Reported side effects include the potential for changes in energy levels, ranging from fatigue and somnolence (sleepiness) to insomnia and anxiety.


Q: Are there long-term health effects associated with taking Fluoxetina?

Official labeling notes that the long-term effects of Fluoxetina are not fully established across all patient groups, as follow-up durations were limited in many primary trials. Long-term studies primarily focus on tracking patterns of symptom recurrence.


Q: How is Fluoxetina processed by the liver and kidneys?

Fluoxetina is primarily processed by the liver using enzymes like CYP2D6. Because the drug and its active components have a long half-life, official guidelines recommend a lower or less frequent dosage for patients with hepatic impairment (liver dysfunction) due to reduced clearance.


Q: Is it safe to drive while taking Fluoxetina?

Official labeling advises caution, noting the drug has the potential for cognitive and motor impairment. Caution is advised regarding the operation of machinery or driving until an individual determines how the medication affects their personal alertness and coordination.


Q: Are there common withdrawal symptoms associated with stopping Fluoxetina?

Withdrawal reactions (or discontinuation syndrome) have been reported when stopping SSRIs. Common symptoms reported can include non-specific issues like nausea and dizziness. Providers often advise a gradual reduction in dosage when discontinuing treatment to help manage these effects.


Q: Is Fluoxetina recommended for people with bipolar disorder?

Fluoxetina is approved for treating depressive episodes associated with Bipolar I Disorder when used in combination with another medicine. However, official warnings state that it may activate mania or hypomania, and patients must be screened for bipolar disorder before initiating treatment.


Q: Can Fluoxetina be taken with or without food?

Official administration guidelines state the medicine may be taken with or without food. Its absorption into the body is not significantly affected by meals.


Q: Does Fluoxetina interact with medicines used for stomach issues?

Yes, Fluoxetina can interact with certain medicines used for stomach issues, such as those that treat nausea and vomiting. This is because some of these drugs can also increase serotonin levels, potentially raising the risk of Serotonin Syndrome.


Q: Is Fluoxetina more effective for certain people or conditions?

Regulatory studies established efficacy separately for different conditions like MDD, OCD, and Bulimia Nervosa. Additionally, official warnings note that effectiveness and safety have not been established for children younger than certain ages for specific indications.


Q: What happens if a dose of Fluoxetina is missed?

Official guidelines state that if a dose is missed, a patient should take the next scheduled dose at the regular time. Official guidelines recommend avoiding the attempt to compensate for a missed dose by taking two doses at once.

How should Fluoxetina be stored and disposed of?

Official Storage and Disposal of Fluoxetine

Fluoxetine must be stored under specific conditions defined in regulatory labeling to maintain its stability and ensure public safety.

Aspect Official Regulatory Requirement
Storage Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), with permitted short excursions. Do not store above 25 C.
Protection Protect from light and moisture. Do not store in damp places like a bathroom.
Container & Handling Keep in the original container, tightly closed. The oral solution form must be protected from freezing.
Child Safety Keep out of the sight and reach of children and pets in a secure, up-and-away location.
Disposal Do not dispose of in household waste or wastewater. Utilize drug take-back programs or discard according to local requirements for pharmaceutical waste. The oral solution must be discarded 60 days after first opening.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluoxetina found in:

A-Z Index: